Are we all global now? Local vs. foreign sources of corporate competence: The case of the Japanese pharmaceutical industry

Strategic Management Journal

Volumn 25, Issue 8-9, 2004, Pages 865-886

  Thomas III, L G ^a  

^a EMORY UNIVERSITY   (United States)

Author keywords

Capability; Institutional environment; Japan; Multinational firm; Pharmaceutical industry

Indexed keywords

COMPETITION; INTERNATIONAL TRADE; INVENTORY CONTROL; MARKETING; PRODUCT DEVELOPMENT; RESEARCH AND DEVELOPMENT MANAGEMENT; RESOURCE ALLOCATION; STRATEGIC PLANNING;

CAPABILITY; INSTITUTIONAL ENVIRONMENT; MULTINATIONAL FIRMS; PHARMACEUTICAL INDUSTRY, JAPAN; STRATEGIC MANAGEMENT;

DRUG PRODUCTS PLANTS;

EID: 4043142256     PISSN: 01432095     EISSN: None     Source Type: Journal    
DOI: 10.1002/smj.420     Document Type: Article

References (76)

1. Acs ZJ, Audretsch DB, Feldman MP. 1994. R&D spillovers and recipient firm size. Review of Economics and Statistics 100: 336-367.
2. Agarwal S, Desai S, Holcomb MH, Oberoi A. 2001. Unlocking the value in big pharma. McKinsey Quarterly (2): 65-73.
3. Akira K. 1993. Understanding Japanese health care expenditures: the medical fee schedule. In Japan's Health System: Efficiency and Effectiveness in Universal Care, Okimoto DI, Yoshikawa A (eds). Faulkner & Gray: Washington, DC; 45-61.
4. Amit R, Schoemaker PJH. 1993. Strategic assets and organizational rent. Strategic Management Journal 14(1): 33-46.
5. Bartlett CA, Ghoshal S. 1989. Managing Across Borders: The Transnational Solution. Harvard Business School Press: Boston, MA.
6. Berger D, Fukunishi I. 1996. Psychiatric drug development in Japan. Science 273(July 19): 318-319.
7. Boeker W. 1988. Organizational origins: entrepreneurial and environmental imprinting at the time of founding. In Ecological Models of Organizations, Carroll G (ed). Ballinger: Cambridge, MA; 33-51.
8. Bresnahan T, Gambardella A, Saxenian AL, 2001. 'Old Economy' inputs for 'New Economy' outcomes: cluster formation in the New Silicon Valleys. Industrial and Corporate Change 10(December): 835-860.
9. Bryan L, Fraser J, Oppenheim J, Rail W. 1999. Race for the World: Strategies to Build a Great Global Firm. Harvard Business School Press: Boston, MA.
10. James Capel & Co. 1995. Japanese Pharmaceuticals. James Capel Pacific Ltd: Tokyo.
11. Christensen CM. 1997. The Innovator's Dilemma. Harvard Business School Press: Boston, MA.
12. Darr ED, Argote L, Epple D. 1995. The acquisition, transfer, and depreciation of knowledge in service organizations: productivity in franchises. Management Science 41(November): 1750-1762.
13. Davis R, Thomas LG. 1993. Direct estimation of synergy: a new approach to the diversity-performance debate. Management Science 39(November): 1334-1346.
14. de Haen P. 1988. Drug Product Index: USA. Paul de Haen: Englewood, CO.
15. Doremus PN, Keller WW, Pauly LW, Reich S. 1999. The Myth of the Global Corporation. Princeton University Press: Princeton, NJ.
16. Dosi G. 1982. Technological paradigms and technological trajectories. Research Policy 11: 147-162.
17. Dosi G, Nelson RR, Winter SG. 2000. Introduction: the nature and dynamics of organizational capabilities. In The Nature and Dynamics of Organizational Capabilities, Dosi G, Nelson RR, Winter SG (eds). Oxford University Press: New York; 1-22.
18. Doz Y, Santos J, Williamson P. 2001. From Global to Metanational: How Companies Win in the Knowledge Economy. Harvard Business School Press: Boston, MA.
19. Dunning JH. 1996. The geographical sources of competitiveness of firms: some results of a new survey. Transnational Corporations 5(3): 1-29.
20. Economist. 1993. Japan's drugs industry: medicinal madness. 326(7804): 73.
21. PDA. 1985. Compendium of New Drug Approvals in Eleven Industrialized Countries, 1970 to 1983. PDA, Office of Planning and Evaluation: Rockville, MA.
22. Foss NJ, Eriksen B. 1995. Competitive advantage and industry capabilities. In Resource-Based and Evolutionary Theories of the Firm: Towards a Synthesis, Montgomery CA (ed). Kluwer Academic: Boston, MA; 43-69.
23. Fukushima M. 1989. The overdose of drugs in Japan. Nature 342(December 21): 850-851.
24. Galbraith JR. 2000. Designing the Global Corporation. Jossey-Bass: San Francisco, CA.
25. Gourieroux C, Monfort A, Trognon A. 1984a. Pseudo maximum likelihood methods: theory. Econometrica 52:681-700.
26. Gourieroux C, Monfort A, Trognon A. 1984b. Pseudo maximum likelihood methods: application to Poisson models. Econometrica 52: 701-720.
27. Griffin JP. 1986. Survey of the spontaneous adverse drug reaction reporting schemes in 15 countries. British Journal of Clinical Pharmacology 21: 835-1005.
28. Griffin JP. 1987. Differences between Protestant and Catholic religious ethos impinge on medical issues. International Pharmacy Journal 1: 145-148.
29. Helfat CE. 1997. Know-how and asset complementarity and dynamic capability accumulation: the case of R&D. Strategic Management Journal 18(5): 339-360.
30. Helfat CE, Lieberman MB. 2002. The birth of capabilities: market entry and the importance of prehistory. Industrial and Corporate Change 11(August): 725-790.
31. Henderson R, Cockburn I. 1994. Measuring competence? Exploring firm effects in pharmaceutical research. Strategic Management Journal, Winter Special Issue 15: 63-84.
32. Henderson R, Cockburn I. 1996. Scale, scope, and spillovers: the determinants of research productivity in drug discovery. Rand Journal of Economics 27(Spring): 32-59.
33. Howells J, Neary I. 1995. Intervention and Technological Innovation: Government and the Pharmaceutical Industry in the U.K. and Japan. Macmillan: London.
34. HSBC. 2000. Pharmaceutical. HSBC Securities (Japan): Tokyo; October 4.
35. Hu YS. 1992. Global or stateless corporations are national firms with international operations. California Management Review 34(Winter): 107-126.
36. Ichniowski C, Shaw K. 1999. The effects of human resource management systems on economic performance: an international comparison of U.S. and Japanese plants. Management Science 45(May): 704-721.
37. Ichniowski C, Shaw K, Prennushi G. 1997. The effects of human resource management practices on productivity: a study of steel finishing lines. American Economic Review 87(June): 291-313.
38. Ikegami N. 1996. Comparison of pharmaceutical expenditure between Japan and the United States, In Containing Health Care Costs in Japan, Ikegami N, Campbell JC (eds). University of Michigan Press: Ann Arbor, MI; 121-131.
39. Ikegami N, Ikeda S, Kawai H. 1998. Why medical care costs in Japan have increased despite declining prices for pharmaceuticals. Pharmacoeconomics 14(Supplement): 97-105.
40. Ingram P, Baum JAC. 1997. Chain affiliation and the failure of Manhattan hotels, 1898-1980. Administrative Science Quarterly 42(March): 68-102.
41. Jaffe AB, Trajtenberg M, Henderson R. 1993. Geographic localization of knowledge spillovers as evidenced by patent citations. Quarterly Journal of Economics 63: 577-598.
42. Japan Pharmaceutical Manufacturers Association. Various years. Data Book. JPMA: Tokyo.
43. Klepper S, Simmons KL. 2000. Dominance by birthright: entry of prior radio producers and competitive ramifications in the U.S. television receiver industry. Strategic Management Journal 21(10-11): 997-1016.
44. Kono C, Palmer D, Friedland R, Zafonte M. 1998. Lost in space: the geography of corporate interlocking directorates. American Journal of Sociology 103(January): 863-911.
45. Krugman P. 1991. Geography and Trade. MIT Press: Cambridge, MA.
46. Masuyama M, Campbell JC. 1996. The evolution of fee-schedule politics in Japan. In Containing Health Care Costs in Japan, Ikegami N, Campbell JC (eds). University of Michigan Press: Ann Arbor, MI; 265-277.
47. McCullagh P, Neider JA. 1983. Generalized Linear Models. Chapman & Hall: London.
48. McKendrick DG, Doner RF, Haggard S. 2000. From Silicon Valley to Singapore: Location and Competitive Advantage in the Hard Disk Drive Industry. Stanford University Press: Stanford, CA.
49. Merck & Co. 2001. The Merck Index (13th edn). Merck: Whitehouse Station, NJ.
50. Milgrom PR, Roberts J. 1990. The economics of modern manufacturing: technology, strategy, and organization. American Economic Review 80(June): 511-528.
51. Milgrom PR, Roberts J. 1995. Complementarities and fit: strategy, structure, and organizational change in manufacturing. Journal of Accounting and Economics 19(March-May): 179-208.
52. Mitchell W, Roehl T, Campbell JC. 1996. Sales, R&D, and profitability in the Japanese pharmaceutical industry, 1981-92. In Containing Health Care Costs in Japan, Ikegami N, Campbell JC (eds). University of Michigan Press: Ann Arbor, MI; 132-142.
53. Nelson RR, Winter SG. 1982. An Evolutionary Theory of Economic Change. Harvard University Press: Cambridge, MA.
54. Nomura Securities Co. Ltd. 1983. Drug Industry in Japan: Nomura Investment Note BR-2-83 Nomura: Tokyo.
55. Odagiri H, Goto A. 1996. Technology and Industrial Development in Japan: Building Capabilities by Learning, Innovation, and Public Policy. Oxford University Press: Oxford.
56. Pfeffer J. 1981. Power in Organizations. Pitman: Marshfield, MA.
57. Pfeffer J, Salancik GR. 1978. The External Control of Organizations: A Resource Dependence Perspsective. Harper & Row: New York.
58. Piore MJ, Sabel CF. 1984. The Second Industrial Divide: Possibilities for Prosperity. Basic Books: New York.
59. Porter ME. 1990a. The Competitive Advantage of Nations. Free Press: New York.
60. Porter ME. 1990b. The competitive advantage of nations. Harvard Business Review 68(2): 73-93.
61. Porter ME. 1996. What is strategy? Harvard Business Review 74(6): 61-78.
62. Porter ME. 1998. Clusters and the new economics of competition. Harvard Business Review 76(6): 77-90.
63. Porter ME, Siggelkow N. 2001. Contextuality within activity systems. Working paper, Wharton School, University of Pennsylvania.
64. Powell WW, Smith-Doerr L. 1994. Networks and economic life. In The Handbook of Economic Sociology, Smelser NJ, Swedberg R (eds). Princeton University Press: Princeton, NJ; 368-402.
65. Saxenian AL. 1994. Regional Advantage: Culture and Competition in Silicon Valley and Route 128. Harvard University Press: Cambridge, MA.
66. Sorenson O, Audia P. 2000. The social structure of entrepreneurial activity: geographic concentration of footwear production in the United States, 1940-1989. American Journal of Sociology 106: 424-462.
67. Sorenson O, Stuart T. 2001. Syndication networks and the spatial distribution of venture capital investments. American Journal of Sociology 106: 1546-1588.
68. Stinchcombe AL. 1965. Social structure and organizations. In Handbook of Organizations, March J (ed), Rand McNally: Chicago, IL; 142-193.
69. Teece DJ, Pisano G, Shuen A. 1997. Dynamic capabilities and strategic management. Strategic Management Journal 18(7): 509-533.
70. Telser LG. 1987. A Theory of Efficient Cooperation and Competition. Cambridge University Press: Cambridge, U.K.
71. Thomas LG. 1990. Regulation and firm size: FDA impacts on innovation. Rand Journal of Economics 21(Winter): 497-517.
72. Thomas LG. 1994. Implicit industrial policy: the triumph of Britain and the failure of France in global pharmaceuticals. Industrial and Corporate Change 3: 451-489.
73. Thomas LG. 2001. The Japanese Pharmaceutical Industry: The New Drug Lag and the Failure of Industrial Policy. Edward Elgar: Cheltenham, U.K.
74. Toyo Keizai Shinposha. Various years. Japan Company Handbook. Toyo Keizai: Tokyo.
75. Yeoh PL, Roth K. 1999. An empirical analysis of sustained advantage in the U.S. pharmaceutical industry: impact of firm resources and capabilities. Strategic Management Journal 20(7): 637-653.
76. Yoshikawa A. 1993. Doctors and hospitals in Japan. In Japan's Health System: Efficiency and Effectiveness in Universal Care, Okimoto DI, Yoshikawa A (eds). Faulkner & Gray: Washington, DC; 63-79.